Triple-Negative Breast Cancer
[Breast Cancer: Targets and Therapy] Researchers present a review of study findings on the effect of statins on clinical outcomes for patients with breast cancer.
Male Occult Triple-negative Breast Cancer With Dermatomyositis: A Case Report and Review of the LiteratureDecember 29, 2017
[OncoTargets and Therapy] In this case report, a patient with male breast cancer developed dermatomyositis.
Breast cancer was previously thought to not be immunogenic in nature, but a subset of patients with breast cancer, primarily with triple negative disease, have exhibited robust levels of tumor infiltrating leukocytes.
Women with triple-negative or HER2-positive breast cancer who achieve a pathologic complete response from neoadjuvant chemotherapy may be able to avoid follow-up breast or lymph node surgery.
Researchers manipulated triple-negative breast cancer cells to make them susceptible to conventional antiestrogen therapy for breast cancer.
Might a Chemical from Celery and Broccoli One Day Yield a New Drug to Prevent Breast Cancer Metastasis?February 07, 2017
Investigators report on their findings from preclinical studies of luteolin injections to prevent lung metastases of triple-negative breast cancer.
CDK 4/6 inhibitors, currently approved for the treatment of estrogen-positive breast cancer, were found to inhibit metastasis in triple-negative breast
Researchers assessed the relationship between immune gene expression and genomic complexity in TNBC in a study presented at SABCS 2016.
At SABCS 2016, researchers presented study findings demonstrating whether neoadjuvant treatment, PARPi-7, BRCAness, and MP1/2 predict response to veliparib plus carboplatin therapy in patients with high-risk breast cancer.
Expression of this hormone receptor may indicate a less aggressive subtype of triple-negative breast cancer and better prognosis for patients with the disease.
An experimental drug, AMPI-109, shows promise as an immunotherapy that sensitizes triple-negative breast cancer cells, enhancing the effectiveness of the drug.
A first-line triplet chemoimmunotherapy regimen comprised of paclitaxel, capecitabine, and bevacizumab followed by capecitabine and bevacizumab alone as maintenance therapy is highly active with a manageable safety profile in patients with triple-negative breast cancer.
A cocktail of 3 drugs shrank triple-negative breast cancer (TNBC) by killing off cancer cells and halting new tumor growth, a new study conducted in mice and lab-grown human cells has shown.
Vitamin D and androgen receptor-targeted therapy successfully reduced growth and induced death of cancerous cells in a cell culture model of triple-negative breast cancer.
A new drug candidate reduced the growth of tumors in a mouse model of triple negative breast cancer (TNBC) by targeting the RNA, or expression, of a gene only expressed in the diseased cells.
Amplification of the JAK2 gene frequently occurs in triple-negative breast cancer (TNBC), suggesting that specific inhibitors of JAK2 should be investigated in TNBC.
[Breast Cancer: Basic and Clinical Research] The review examines the standard systemic and future treatment options in metastatic triple-negative breast cancer.
Adrenaline acted on breast cancer cells via the cell surface beta2-adrenoceptor to promote disease growth and invasion, suggesting that beta-blockers might be helpful as adjuvant therapy for patients with aggressive breast cancer.
Adding Carboplatin to Neoadjuvant Therapy for Triple-negative Early Breast Cancer Improves Disease-free SurvivalDecember 09, 2015
Carboplatin added to anthracycline/taxane-based neoadjuvant chemotherapy significantly improved pathological complete response rates in patients with triple-negative breast cancer in two large phase IIb studies: GeparSixto and CALGB 40603. Researchers reported on disease-free survival for GeparSixto after median 35 months of observation at the 2015 San Antonio Breast Cancer Symposium.
Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult-to-treat and aggressive form of the disease.
Understanding the Triple Negative Breast Cancer Patient: Tips and Tools for Health Care ProfessionalsOctober 21, 2015
Although treatment options are different and recurrence rates higher for triple negative breast cancer, patients with this subtype of the disease can be hopeful for good treatment outcomes.
A diet that starves triple-negative breast cancer cells of an essential nutrient primes the cancer cells to be more easily killed by targeted treatment.
Enzalutamide may be a viable alternative therapy over cytotoxic chemotherapy for individuals with triple-negative breast cancer, according to a study presented at the 2015 American Society of Clinical Oncology annual meeting.
A new study reveals specific genetic alterations that appear to impact the prognosis and survival rates of African American women.
Preliminary study results indicate that an experimental immune system drug is generally safe and well tolerated in women with metastatic, triple-negative breast cancer.
Researchers have learned more about breast cancer, including identification of a gene that drives the aggressive disease.
Specific methylation patterns revealed in the primary biopsy breast cancer cells of breast cancer DNA methylome can indicate a better or worse prognosis.
Effectiveness of nanoparticle drugs was hindered by tumor microenvironment in triple-negative breast cancerJanuary 29, 2015
Nanoparticle drugs were considered to be a potential silver bullet against cancer, but they have not produced the anticipated improvement in overall survival rates.
Pembrolizumab was well tolerated and yielded durable responses in patients with metastatic triple-negative breast cancer, according to recent trial data.
Deleterious mutations were identified in 14.6 percent of patients in a cohort unselected for family history.
Sign Up for Free e-newsletters
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- When There Are No Words: Interpreting Patients' and Families' Subtle Messages
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|